Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Decoding lysophosphatidic acid signaling in physiology and disease: mapping the multimodal and multinodal signaling networks

Nadhan R., Nath K., Basu S., Isidoro C., Song YS., Dhanasekaran DN.

Clinical Trial on Neuroinflammation, Immune Modulation, published in Signal Transduct Target Ther (2025) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Signal Transduct Target Ther (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41068071
PMCID
PMC12511386
DOI
10.1038/s41392-025-02423-4
Citations
9

Abstract (original English)

Lysophosphatidic acid (LPA) signaling has emerged as a central regulatory axis in both normal physiology and disease, orchestrating diverse cellular processes such as proliferation, survival, migration, immune modulation, and tissue remodeling. Originally identified as a bioactive lipid that regulates smooth muscle contraction and vascular tone, LPA has since emerged as a pleiotropic signaling molecule implicated in multiple physiological systems and a wide spectrum of pathological states. These include cancer, neurodegenerative disorders, cardiovascular and metabolic syndromes, inflammatory conditions, and fibrotic diseases. Elevated LPA levels, overexpression of autotaxin (ATX), and aberrant activation of LPA receptors (LPARs) contribute to disease initiation and progression, positioning the LPA axis as both a diagnostic biomarker and a promising therapeutic target. This review describes the multimodal and multinodal organization of the LPA signaling network, detailing upstream biosynthesis, receptor diversity, and downstream effectors across diverse organ systems. Therapeutic strategies targeting ATX, LPARs, and intracellular mediators are critically assessed, along with a review of ongoing and emerging clinical trials. Furthermore, we introduce a context-aware AI-based neural network model to simulate LPA signaling dynamics, providing a framework for predictive modeling and

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
AnimalsHumansNeoplasmsNeurodegenerative DiseasesPhosphoric Diester HydrolasesLysophospholipidsReceptors, Lysophosphatidic AcidSignal TransductionLysophospholipase D

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research